Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SEELOS THERAPEUTICS, INC.SEEL · Entity 93662 | Director | January 04, 2024 | January 08, 2024 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director · President & CEO | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2034-01-04 | Direct | 1,666 |
Reported balance
After 2024-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 1,666 · Balance 1,666 F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 2,572,441 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Grant · Acquired 221,667 · Balance 2,720,958 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. Row 2 · 2026-07-29 · Sale · Disposed 148,517 · Balance 2,572,441 F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2021 Filed Jan 8, 2021 16:30 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001136261-21-000003 · primary_doc.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 6, 2021, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 369,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001209191-21-002104 · doc4.xml · derivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,000 Underlying: Common Stock · 369,000 shares Expires 2031-01-04 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 16,973 | $5.80 | $98,443.40 |
DisclosureSEC source: 0001209191-21-002104 · doc4.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899,792 F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 40,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002104 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916,765 F4 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 33.33% of which vested on January 4, 2021 upon the achievement of a non-financial performance goal. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 164,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002104 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,432 F3 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 03, 2021 Filed Jan 6, 2021 21:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 31,545 | $5.63 | $177,598.35 |
DisclosureSEC source: 0001209191-21-002104 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,712,432 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. F2 · balance_after: Includes 1,614 shares acquired on November 20, 2020 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:18 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock | 19,192 | $6.25 | $119,950.00 |
DisclosureSEC source: 0001209191-20-050732 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,742,363 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:18 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock | 55,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050732 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,761,555 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 15, 2020 upon the achievement of a non-financial performance goal. F2 · balance_after: Includes 1,743 shares acquired on May 20, 2020 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 19, 2020 Filed Jan 21, 2020 22:39 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 3,195 | $7.18 | $22,940.10 |
DisclosureSEC source: 0001209191-20-004314 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,704,312 F1 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 16:31 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001136261-20-000009 · primary_doc.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on February 6, 2020, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 03, 2020 Filed Jan 4, 2020 01:01 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 345,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-20-001426 · doc4.xml · derivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 345,000 shares Expires 2030-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2020 Filed Jan 4, 2020 01:01 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 6,782 | $7.77 | $52,696.14 |
DisclosureSEC source: 0001209191-20-001426 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,707,507 F3 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2020 Filed Jan 4, 2020 01:01 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 153,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001426 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,714,289 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 804 shares acquired on May 20, 2019 and November 20, 2019 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 18:08 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001136261-19-000109 · primary_doc.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-03-20 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on April 20, 2019, and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 18:08 UTC | SEELOS THERAPEUTICS, INC. SEEL · Entity 93662 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001136261-19-000109 · primary_doc.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on March 20, 2020, and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 19, 2019 Filed Jan 23, 2019 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 4,333 | $8.78 | $38,043.74 |
DisclosureSEC source: 0001209191-19-004858 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560,152 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 01:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 235,554 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-19-001568 · doc4.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,554 Underlying: Common Stock · 235,554 shares Expires 2029-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 01:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 80,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001568 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564,485 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. 25% of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 576 shares acquired on November 20, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| May 04, 2018 Filed May 9, 2018 00:37 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 10,086 | $4.22 | $42,562.92 |
DisclosureSEC source: 0001209191-18-028717 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,012 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 22:41 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-18-004972 · doc4.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2028-01-19 F2 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 22:41 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004972 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,098 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 00:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 34,931 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002389 · doc4.xml · derivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,931 Underlying: Common Stock · 34,931 shares Expires 2027-01-05 F2 · shares: The Reporting Person's employment agreement with the Issuer entitles him to an annual cash bonus. The Reporting Person voluntarily elected to be paid 25% of his 2016 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 00:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-17-002389 · doc4.xml · derivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.